tailieunhanh - Báo cáo y học: "To JUPITER and beyond: Statins, inflammation, and primary preventio"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học quốc tế cung cấp cho các bạn kiến thức về ngành y đề tài: To JUPITER and beyond: Statins, inflammation, and primary prevention. | Rao and Milbrandt Critical Care 2010 14 310 http content 14 3 310 CRITICAL CARE JOURNAL CLUB CRITIQUE L To JUPITER and beyond Statins inflammation and primary prevention Ajay D Rao1 and Eric B Milbrandt 2 University of Pittsburgh Department of Critical Care Medicine Evidence-Based Medicine Journal Club edited by Eric B Milbrandt Expanded Abstract Citation Ridker PM Danielson E Fonseca FAH Genest J Gotto AM Kastelein JJP Koenig W Libby P Lorenzatti AJ MacFadyen JG Nordestgaard BG Shepherd J Willerson JT Glynn RJ Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 2008 359 2195-2207 1 . Background Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. Methods Objective To investigate whether treatment with rosuvastatin 20 mg daily as compared to placebo would decrease the rate of first major cardiovascular events. Design Randomized double-blind placebo-controlled multicenter trial. Setting 1315 sites in 26 countries. Subjects 17 802 apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less than 130 mg per deciliter mmol per liter and high-sensitivity C-reactive protein levels of mg per liter or higher. Intervention Subjects were randomly assigned to rosuvastatin 20 mg daily or placebo. Outcomes The primary outcome was the occurrence of a first major cardiovascular event defined as myocardial infarction stroke arterial revascularization hospitalization for unstable angina or death from cardiovascular causes. Secondary endpoints included the components of the primary end point considered individually as well as death from any cause. Results The trial was .